Abl Bio Inc.

I-mab Biopharma US Limited

Yuhan Corporation

I-mab Biopharma Co., Ltd.

Eunsil Sung

Hyejin Chung

Yeunju Kim

Byungje Sung

Yangsoon Lee

Eunyoung Park

Youngdon Pak

Jinhyung Ahn

Sang Hoon Lee

Juhee Kim

Kyeongsu Park

Kyungjin Park

Yong-Gyu Son

Daehae Song

Jaehyun Eom

Jaeho Jung

Dongin Kim

Lei Fang

Wenqing Jiang

Eun-Jung Lee

Donghoon Yeom

Jiseon Yoo

Minji Park

Ui-Jung Jung

Jinwon Jung

Sungwon An

Hyoju Choi

Seung-Jae Lee

Tae Kyung Kim

Bora Lee

Bingshi Guo

Zhengyi Wang

Moo Young Song

Na Rae Lee

Eunjung Kim

Young Bong Park

Seawon Ahn

Uijung Jung

YoungKwang Kim

Weon-Kyoo You

Yeryoung Yong

Wonjun Son

Sang-Jun Ha

Myeong Joon Kim

Weonkyoo You

Min Sun Choi

Yoseob Lee

Yonggyu Son

The present disclosure provides an anti-PD-L1/anti-4-1BB bispecific antibody capable to effectively block the interactions between PD-L1 and its receptor PD-1 and between 4-1BB and its ligand. The bispecific antibody may have high binding affinity to both of a PD-L1 protein and a 4-1BB protein.

Anti-PD-L1/anti-4-1BB bispecific antibodies and uses thereof

Provided are an anti-4-1BB/anti-EGFR bispecific antibody, and a pharmaceutical composition and a method for treating and/or preventing a cancer using the same.

Anti-EGFR/anti-4-1BB bispecific antibody

The present invention discloses an anti-ROR1 antibody specifically recognizing human and mouse ROR1. The monoclonal antibody can be usefully used for cancer targeting treatment including detection of various cancer expressing ROR1 through specific binding, and drug delivery to specific cancer, etc. as well as a cancer therapeutic agent, by inhibiting tumors.

Anti-ROR1 antibody and use thereof

The present invention relates to a bi-specific antibody that specifically binds to alpha-synuclein and IGF1R, and use of the bi-specific antibody for treating or diagnosing synucleinopathies associated with alpha-synuclein or alpha-synuclein aggregates. The IGF1R portion of the bi-specific antibody acts as a shuttle to penetrate the blood brain barrier, allowing the alpha-synuclein portion to exert its action in the brain. Further, the half-life of the bi-specific antibody may be extended to maintain efficacy over time.

Bispecific antibody to alpha-synuclein/insulin-like growth factor 1 receptor and use thereof

The disclosure discloses anti α-Syn antibodies preferentially recognizing α-Syn aggregates. The antibodies of the present invention bind to α-Syn aggregates with high affinity and specificity and inhibit accumulation or intercellular transfer of α-Syn aggregates, and thus can be used for detection, diagnosis and/or treatment or prevention of various diseases caused by the accumulation of α-Syn aggregates.

Anti-alpha-synuclein antibodies and uses thereof

Provided is an anti-B7-H3 antibody specifically recognizing a B7-H3, which can be usefully as a cancer therapeutic agent, as having an inhibitory activity of an immune checkpoint which induces antibody-dependent cell-mediated cytotoxicity and T cell activation inhibited by B7-H3. In particular, the antibody having the inhibitory activity of an immune checkpoint can be used in combination with other immunoantibody therapeutic agents. In addition, it can be usefully used for cancer targeting treatment including detection of various cancers expressing B7-H3 through specific binding to B7-H3, and drug delivery to specific cancer, etc.

Anti-B7-H3 antibody and use thereof

Provided are bispecific and multi-specific antibodies that target both claudin 18.2 (CLDN18.2) and 4-1BB. These antibodies, in the absence of CLDN18.2-expressing cells, can bind to 4-1BB but are unable to activate 4-1BB signaling. In the presence of CLDN18.2-expressing cells, however, these antibodies can trigger CLDN18.2-dependent 4-1BB signaling, leading to potent immune response to the CLDN18.2-expressing tumor cells.

Anti-claudin 18.2 and anti-4-1BB bispecific antibodies and uses thereof

Growing community of inventors

Seongnam-si, South Korea

Eunsil Sung